A Phase 1/2a Open-Label Multi-Center Trial to Assess Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of CLN-081 in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically or cytologically confirmed recurrent and/or metastatic Non-Small Cell Lung Cancer (NSCLC). 2. Documented EGFR exon 20 insertion mutation.

You may not be eligible for this study if the following are true:

  • 1. For prior Exon 20 patients only: No Prior treatment with an EGFR exon 20 insertion-targeting drug (e.g., poziotinib, TAK788, tarloxotinib, JNJ- 61186372). 2. For all patients: Have any unresolved toxicity of Grade =2 from previous anti-cancer treatment, except for alopecia and skin pigmentation.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.